# A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

> **NCT02181413** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 656 (actual)

## Conditions studied

- Multiple Myeloma
- Autologous Stem Cell Transplant

## Interventions

- **DRUG:** Ixazomib Citrate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02181413
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-16
- **Primary completion:** 2018-04-16
- **Final completion:** 2023-09-08
- **Target enrollment:** 656 (ACTUAL)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181413, "A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02181413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*